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Abstract
Context: Von Hippel–Lindau (VHL) disease manifests as a variety of benign and 
malignant neoplasms. Previous studies of VHL disease have documented several 
genotype–phenotype correlations; however, many such correlations are still unknown. 
Increased identification of new mutations and patients with previously described 
mutations will allow us to better understand how VHL mutations influence disease 
phenotypes.
Patients and design: A total of 45 individuals from five unrelated families were 
evaluated, of which 21 patients were either diagnosed with VHL disease or showed 
strong evidence related to this disease. We compared the patients’ gene sequencing 
results with their medical records including CT or MRI scans, eye examinations and 
laboratory/pathological examinations. Patients were also interviewed to obtain 
information regarding their family history.
Results: We identified four missense mutations: c.239G>T (p.Ser80Ile), linked with VHL 
Type 2B, was associated with renal cell carcinoma, pheochromocytoma and hemangioma 
in the cerebellum; c.232A>T (p.Asn78Tyr) manifested as RCC alone and likely caused VHL 
Type 1; c.500G>A (p.Arg167Gln) mutation was more likely to cause VHL Type 2 than Type 
1 as it preferentially induced Pheo and HB in the retina, cerebellum and spinal cord; 
c.293A>G (p.Try98Cys) was associated with Pheo and thus likely induced VHL Type 2.
Conclusions: Characterizing VHL disease genotype–phenotype correlations can enhance 
the ability to predict the risk of individual patients developing different VHL-related 
phenotypes. Ultimately, such insight will improve the diagnostics, surveillance and 
treatment of VHL patients.
Precis: Four missense mutations in VHL have been identified in 21 individuals when five 
unrelated Chinese families with VHL disease were analyzed; VHL mutations are highly 
associated with unique disease phenotypes.
Introduction
Von Hippel–Lindau (VHL) disease is a rare autosomal 
dominant disease that manifests as a variety of benign 
and malignant neoplasms, including retinal hemangioma 
(HB), HB of the central nervous system (CNS), pancreatic 
neuroendocrine tumor (NET) or cystadenoma, 
pheochromocytoma (Pheo) and clear cell renal cell 
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carcinoma (RCC) (1, 2). VHL disease is primarily caused 
by inactivation of the VHL tumor-suppressive protein. 
A dysfunctional VHL leads to reduced ubiquitylation 
and proteasomal degradation of the hypoxia-inducible 
factors (HIFs), HIF-1α and HIF-2α. Elevated levels of HIFs 
subsequently result in overactivation of the downstream 
pathways involved in vascular endothelial growth factor, 
platelet-derived growth factor and transforming growth 
factor-α (3). Patients with VHL disease exhibit diverse 
phenotypes. For example, some patients manifest either 
RCC or Pheo, and some with both. VHL disease is generally 
classified into two subtypes: Type 1 (without Pheo) and 
Type 2 (with Pheo) (4). Type 2 disease can be further 
divided into three sub-categories: Types 2A, 2B and 2C. 
Patients with Pheo and HB in the CNS, but without RCC 
were considered as Type 2A; patients with Pheo, RCC and 
other CNS tumors were known as Type 2B, while those 
with Pheo alone were categorized as Type 2C.
VHL mutation-induced RCC typically develops 
between the ages of 20 and 50 years but rarely in patients 
younger than 20  years old (5). This type of RCCs is 
often multi-centric and bilateral, arising in conjunction 
with both cysts and de novo from the non-cystic renal 
parenchyma. In addition, they usually develop at multiple 
sites in the kidneys with approximately two-thirds of 
such patients showing multiple renal cysts and RCCs (5). 
Pancreatic abnormalities are also common in patients 
with VHL disease, as about 77% of these patients have 
different pancreatic lesions, such as cysts (47%), serous 
cystadenomas (11%) and NETs (15%) (5). VHL mutation-
induced Pheo usually develops in the adrenal gland or 
paraganglia at different ages ranging from <10  years to 
>40  years with about 18% of them at a median age of 
30 years (6). Pheos are often multiple, bilateral or extra-
adrenal and are usually asymptomatic. HBs are rare 
indolent vascular tumors that may occur sporadically 
(75%) or in association with VHL disease (25%). 
VHL-associated HBs are frequently multiple and develop 
during childhood (<10  years) or in the early teens to 
thirties. HB most commonly developed in the cerebellum 
(5–30%) and spinal cord (80%) (6).
Variations in disease penetrance have long been 
recognized in close relation to genotypes. Previous 
studies have documented that specific VHL mutations 
are associated with distinct patterns of tumor formation 
(7). Since some data suggest that the same mutation 
might cause different VHL types in different races (8, 9), 
it is critical to fully characterize genotype–phenotype 
correlations of this disease in different patient populations. 
In this study, we reported five unrelated Chinese families 
with VHL disease and analyzed the genotype–phenotype 
correlations in this population.
Subjects and methods
Patients
A total of 45 individuals from five unrelated families were 
evaluated. Among them, 21 patients were either diagnosed 
with VHL disease or showed strong evidence related to 
this disease. Based on one of the recent review articles (2), 
VHL is the only gene in which mutations are known to 
cause VHL disease and these patients have the mutations 
resulting in loss-of-function of VHL protein (the genetic 
criteria). The clinical criteria for VHL disease include (i) 
a positive family history of HB, RCC, Pheo or pancreatic 
tumors or cysts and epididymal cystadenoma; (ii) HB in 
combination with other tumors including RCC, Pheo, 
pancreatic tumors or cysts or epididymal cystadenoma 
without a positive family history of VHL disease (2). The 
patients’ gene sequencing results were compared with 
their medical records including CT or MRI scans, eye 
examinations and laboratory/pathological examinations. 
Additional information regarding to their family history 
was obtained by further interviewing.
Compliance with ethical standards
All procedures involving human participants were 
performed in accordance with the ethical standards of 
the Institutional Research Committee, the 1964 Helsinki 
Declaration and its later amendments or comparable 
ethical standards. The Daping Hospital of Third Military 
Medical University waived Institutional Review Board 
approval for the study. However, written informed 
consent for the use of medical records and related images 
was obtained from all patients.
Genetic analysis
Total DNA isolated from the peripheral blood of all 
five probands was screened for potential mutations 
in the following susceptibility genes of Pheos and/or 
RCC: SDHAF2 (succinate dehydrogenase complex 
assembly factor 2), SDHB (succinate dehydrogenase 
subunit B), SDHC (succinate dehydrogenase subunit 
C), SDHD (succinate dehydrogenase subunit D), MAX 
(MYC-associated factor X), NF1 (neurofibromin 1), RET 
(rearranged during transfection), VHL, FH (fumarate 
hydratase), FLCN (folliculin), and MET using Target 
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Capture-Based Deep Sequencing (BGI Health, Shenzhen, 
Guangdong, China). Upon identification of mutations 
in the probands, the potential mutations in most of 
the respective family members were further screened by 
Sanger sequencing.
Results
Cases
Patient 1
A 42-year-old female was admitted to our hospital in May 
2015 due to masses in her right kidney and left adrenal 
gland. The CT scan showed a mass of 2.5 × 2.1 cm and 
multiple cysts in her right kidney (Fig. 1A, upper image), 
and a mass of 6.1 × 3.9 cm in her left adrenal gland 
(Fig. 1A, middle image), while a MRI of her head showed 
a lesion in her right cerebellum (1.0 × 1.4 cm). In addition, 
two large masses (>6 cm) were found in her bilateral 
adrenal glands when she was 29 years old, for which she 
repeatedly underwent adrenal Pheo resection. At 38 years 
of age, she underwent pancreatic mass resection and 
pathological analysis of the mass showed a pancreatic NET. 
Considering her recurrent and multiple lesions, surgery 
was not considered suitable and therefore sunitinib was 
prescribed. A few months later, she experienced dizziness, 
headache and emesis. In February 2016, she underwent 
surgery for the mass in her right cerebellum (Fig.  1A, 
bottom image), and HB was confirmed pathologically. In 
addition, her eldest brother had RCCs in both kidneys, 
HBs in his bilateral cerebellums and Pheo in his left 
adrenal gland. Her second brother also had RCC, while her 
daughter had Pheos in her bilateral adrenal glands and HB 
in her left cerebellum. The patient’s father died from brain 
Figure 1 Representative CT and MRI scans from the probands. (A) CT and MRI scans showing lesions in proband 1, including a right renal cell carcinoma 
(RCC) (upper image) and left pheochromocytoma (Pheo) (middle image) by CT scan, and a hemangioma (HB) in the right cerebellum (bottom image) by 
MRI scan. (B) A CT scan showing RCCs in proband 2. (C) CT scans of Pheos (upper image) and a renal cyst (bottom image) in proband 3. (D) CT and MRI 
scans showing the Pheos (upper image) and HB (bottom image) in proband 4. (E) CT scans showing Pheos in proband 5. Red arrows indicate the relevant 
features.
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tumors. Although without pathological confirmation, he 
was most likely suffered HBs based on the family history. 
Therefore, we conducted gene sequencing of her DNA 
and a pathogenic VHL mutation (c.239G>T; p.Ser80Ile) 
(Fig. 2A) was confirmed.
Patient 2
A 50-year-old female was referred to our hospital in 
August 2011 for masses in her left kidney (Fig.  1B). 
The CT scan showed several masses in her left kidney and 
the largest one was about 3.1 × 2.4 cm. She underwent a 
radical nephrectomy 5  years ago for the tumor in her 
right kidney. Given the fact that she had already lost 
one kidney, sunitinib instead of surgery was prescribed. 
Sanger sequencing for potential VHL mutation was 
conducted for her and her family members and 
c.232A>T (p.Asn78Tyr) mutation was identified in her, 
her mother, sister, brother and nephew (Fig. 2B). In fact, 
her sister was diagnosed with a pancreatic NET and died 
of hemorrhagic stroke at the age of 40  years, and her 
mother died of stroke at 50 years of age. Her brother and 
nephew refused further examinations for VHL-related 
lesions.
Patient 3
The patient was a 24-year-old male who presented with 
masses in his bilateral adrenals. In February 2013, he 
underwent an abdominal CT scan that revealed masses 
in his bilateral adrenals (Fig. 1C, upper image) and a cyst 
in his left kidney (Fig.  1C, bottom image). The masses 
were subsequently resected by laparoscopic surgery and 
pathological analysis confirmed the presence of Pheos. 
His mother and aunt died from HBs in their brain, while 
his sister and cousin had Pheos in their bilateral adrenals 
and right adrenal, respectively. We decide to sequence the 
relevant susceptible genes in the proband and confirmed 
that he had a heterozygous missense VHL mutation 
c.500G>A (p.Arg167Gln) (Fig. 2C).
Patient 4
A 21-year-old male reported blurry vision and 
metamorphopsia in his left eye for 10 days beginning 
on November 9, 2015. An eye examination discovered 
a macular hole for which he underwent an operation. 
Tissue pathology revealed an HB in his left retina. After 
8  months, he was again referred to our hospital for 
masses in his bilateral adrenals (Fig. 1D, upper image). 
These masses were subsequently resected and the 
pathological report confirmed the presence of Pheos. 
Additionally, the MRI scan showed a mass in his basal 
ganglia region (Fig.  1D, bottom image), a mass in his 
left frontal lobe, as well as a mass in his cervical cord, 
which were most likely CNS HBs. Sequencing identified 
the same heterozygous missense mutation as the family 
of patient 3, p.Arg167Gln (Fig.  2D). Additionally, he 
revealed that his father also had Pheos in his bilateral 
adrenals.
Figure 2
Gene sequencing data reveal VHL mutations for Families 1 (A), 2 (B), 3 (C), 
4 (D), and 5 (E), respectively.
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Patient 5
The patient was a 10-year-old male who presented with 
dizziness and headache for 1 month and blurry vision for 
2 weeks. An abdominal CT scan revealed two masses in 
his bilateral adrenals (Fig. 1E) and Pheos were confirmed 
pathologically. Sequencing screening identified a 
heterozygous missense mutation (c.293A>G; p.Try98Cys) 
in VHL (Fig. 2E). Additionally, both his grandmother and 
mother had Pheos in their bilateral and left adrenals.
Clinical characteristics of patients
In this study, we analyzed a total of 21 patients from five 
unrelated families who were either diagnosed with VHL 
disease or showed strong evidence support the conclusion 
of this disease (Table 1) and their family pedigrees were 
shown in Fig.  3. Among all the VHL disease-associated 
tumors, Pheo was the most common one (n = 10, 5 men 
and 5 women), followed by HB (n = 7, 3 men and 4 
women) and RCC (n = 3, 1 men and 2 women). RCC, Pheo 
and HB frequently manifested bilaterally or as multiple 
lesions. Among this particular cohort, CNS HB is the 
leading cause of death due to HB-related hemorrhagic 
stroke. Routine eye examinations might be critical for 
identifying early manifestations of VHL pathogenesis so 
patient care can be managed at earlier points in disease 
progression. Two probands were admitted to hospital 
because of blurry vision. Wang et al. have described that 
HB in CNS and retina represent the most prevalent VHL-
associated tumors. By conditional inactivating VHL in a 
hemangioblast population using a Scl-Cre-ERT2 transgenic 
mouse line, they found that affected VHL-mutant mice 
demonstrated retinal vascular lesions associated with 
prominent vasculature, anomalous capillary networks, 
hemorrhage, exudates and localized fibrosis (10).
Genotype–phenotype correlations
Four missense mutations were identified in these five 
unrelated Chinese families, specifically, c.239G>T 
(p.Ser80Ile) in family 1, c.232A>T (p.Asn78Tyr) in family 
2, c.500G>A (p.Arg167Gln) in both family 3 and 4 and 
c.293A>G (p.Try98Cys) in family 5. All affected members 
in Family 1 presented with RCC, Pheo and HB in their 
cerebellum, indicating that the mutation (c.239G>T; 
p.Ser80Ile) is likely linked to VHL Type 2B. In Family 2, only 
RCC developed in the affected individuals, suggesting that 
this specific mutation (c.232A>T; p.Asn78Tyr) leads to VHL 
Type 1. Pheos and HBs developed more frequently in the 
members of families 3 and 4 who bore the same mutation 
(c.500G>A; p.Arg167Gln), indicating that this mutation 
is likely responsible for VHL Type 2 rather than Type 1. 
The proband in family 5 presented with both Pheo and 
HB, suggesting that the c.293A>G (p.Try98Cys) mutation 
is also linked to VHL Type 2. Although both mutations in 
families 3/4 and 5 resulted in Pheos, the tumors carrying 
different mutations might have diverse characteristics. 
The hormone expression profiles of proband 4 and 5 
(Table 2) showed that the Pheo in proband 4 (c.500G>A; 
p.Arg167Gln) might be non-functional, while the Pheo in 
proband 5 (c.293A>G; p.Try98Cys) could cause hormonal 
change and result in the hypertension.
Discussion
In this study, we identified four missense mutations in 
five unrelated families with VHL disease and analyzed 
the genotype–phenotype correlation in this small 
cohort. Based on the genetic mutations and the clinical 
diagnoses, we inclined to make the following conclusions: 
the mutation c.239G>T; p.Ser80Ile is associated with 
Figure 3 Family pedigrees for probands 1 (A), 2 
(B), 3 (C), 4 (D), and 5 (E), respectively. ‘I, II, III’ 
represent generations, ‘□, ○’ indicate normal 
males and females, ‘●, ■’ represent male and 
female carriers of the corresponding VHL 
mutation, dashes between symbols ‘□–○’ 
indicate a couple and ‘↗’ indicates the probands.
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RCC, Pheo and HB in the cerebellum, while the mutation 
c.232A>T; p.Asn78Tyr tended to cause RCC alone; the 
mutation c.500G>A; p.Arg167Gln preferentially caused 
Pheo and HB in the retina, cerebellum and spinal cord; 
the mutation c.293A>G; p.Try98Cys is associated with 
Pheo alone.
All four mutations identified in this study have 
been reported previously. The mutation c.239G>T; 
p.Ser80Ile has been reported to be associated with both 
VHL Types 1 (11) and Type 2 (12, 13). However, this 
particular mutation in the Chinese family specifically 
caused VHL Type 2B. Using molecular modeling of the 
VHL–ElonginC–HIF–1alpha complex, the mutation 
c.232A>T; p.Asn78Tyr identified in the current study was 
previously predicted to be highly associated with RCC, 
and therefore, to cause VHL Type 1 (14). We found that 
the mutation c.500G>A; p.Arg167Gln in two unrelated 
families. This mutation has been first reported by Hes 
et al. in three families, of which four patients had RCCs 
and three had renal cysts (15) and later by Ciotti et al. in 
another two patients (16). In the latter report, one patient 
presented with bilateral RCCs while the other suffered 
RCCs and both pancreatic and renal cysts. Therefore, this 
mutation-associated disease is classified as VHL Type 1 due 
to the absence of Pheo. In the current study, this mutation 
was associated with both Pheo and HB, and therefore, we 
suggest that in Chinese population, this mutation-caused 
VHL disease should be classified as Type 2. However, we 
are unable to further determine if it is specific for Type 2A 
or Type 2B due to the limited size of cohort. The mutation 
c.293A>G, p.Try98Cys was previously described in two 
Chinese patients, one of them presented with HB and 
Pheo, while the other only showed HB. In the current 
study, the affected patients in family 5 experienced Pheo 
only. Therefore, this mutation should be classified as VHL 
Type 2 in the Chinese population.
Patients with VHL disease exhibit diverse phenotypes. 
Many factors may underlie this phenotypic diversity, 
including the kind or site of the VHL mutation, the 
type of amino acid substitutions, modifier genes or 
other environmental factors. Of note, different kinds of 
mutations can produce remarkably diverse phenotypes. 
In VHL patients from non-Chinese population, VHL 
deletions or truncations are associated with VHL Type 
1, while missense mutations are more likely to cause 
VHL Type 2 (7). This is because VHL missense mutations 
confer a high risk in development of Pheos (17), while 
VHL deletions and truncations confer a higher risk of 
CNS HB relative to missense mutations (18). The findings 
from a cohort of a large Chinese population also support 
the notion that missense mutation confers a high risk of 
Pheos development in Chinese VHL patients (19). All four 
mutations identified in our study were missenses and only 
one of them caused VHL Type 1, while the other three 
resulted in VHL Type 2. These findings also support the 
notion that missense mutations intend to lead to Pheo.
Mutations at different sites are associated with diverse 
risks of VHL-related lesions. For instance, mutations in 
the Missense Cluster Regions MCR-1 (residues 74–90) 
and MCR-2 (residues 130–136) increase the risk of renal 
lesions (20). The mutations p.Tyr98His and p.Tyr112His 
confer a low risk for RCC, while p.Tyr98His, p.Ser111Cys, 
p.Arg161Gln, p.Leu178Gln and p.Leu188Val confer 
a high risk of Pheo (7). It has been reported that 
c.241C4T (p.Pro81Ser) missense mutation increases the 
risk of RCC and CNS HB (21), while the p.Pro86Leu 
Table 2 Patients’ hormone expression profiles.
Hormone Reference range Proband 4 Proband 5
Cortisol 8 (ng/mL) 50–280 241 312
Cortisol 16 (ng/mL) 20–140 135 381
Cortisol 24 (ng/mL) 10–120 81 128
ACTH 8 (pg/mL) 5.08–32.8 16.9 —
ACTH 16 (pg/mL) 10.7–30.5 24.0 —
ACTH 24 (pg/mL) 5–15 12.5 —
Vanillylmandelic acid (μmol/24 h urine) 9.6–50.0 28.1 116.8
17-Hydroxycorticosteroid (μmol/24 h urine) 5.5–33.2 16.4 11.3
17-Ketosteroid (μmol/24 h) 13.9–76.3 67.2 40
Orthostatic aldosterone (ng/mL) 0.1–0.3 0.1 0.1
Clinostatic aldosterone (ng/mL) 0.1–0.2 0.1 0.2
Orthostatic renin activity (ng/mL/h) 0.3–5.2 3.4 17.9
Clinostatic renin activity (ng/mL/h) 0.1–1.5 1.0 17.1
Orthostatic angiotensin II (pg/mL) 19–115 79 322
Orthostatic angiotensin II (pg/mL) 15–97 55 306
Hypertension No Yes
ACTH, adrenocorticotropic hormone.
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mutation preferentially induces HB (22). Our findings 
further substantiated this notion. More importantly, 
we found that the same tumor (Pheo) resulted from 
different mutations manifest different characteristics. 
The mutation c.500G>A; p.Arg167Gln in proband 4 
caused non-functional Pheo, while mutation c.293A>G; 
p.Try98Cys in proband 5 resulted in hormonal changes 
and subsequent hypertension. This finding need to be 
further substantiated in a large cohort study.
Different mutations of the same codon can also 
produce variable phenotypes. Bradley et  al. suggest that 
missense mutation c.334T>A (p.Tyr112Asn) caused VHL 
Type 1 since most (53.8%) of the affected family members 
presented with RCC and only one with Pheo (23). On 
the other hand, substitution of histidine for asparagine 
(c.334T>C) increases the risk of VHL Type 2A as all the 
members in two American families (22 patients) carrying 
this mutation had Pheo and none with RCC (24). It has 
been speculated that such large phenotypic variation 
may resulted from different stabilities of the VHL protein 
produced by different amino acid substitutions. By 
studying mice carrying VHL-null and Type 2B mutant, 
Alexandra et al. demonstrated that diverse phenotypes are 
likely resulted from differential effects of specific mutation 
on vascular development via downstream perturbations 
in Notch signal and in conjunction with other pathway 
misregulation (25).
Although most mutations lead to similar genotype–
phenotype correlations across races (26), the same 
mutation in patients of different races may also manifest 
diverse phenotypes. Crossey et  al. showed that the 
mutations p.Arg113Ter, p.Gln132Ter, p.Leu158Val and 
p.Cys162Tyr are associated with VHL Type 1 in western 
cultures (8), whereas a later report by Yoshida et  al. 
suggested that these mutations are associated with VHL 
Type 2 in Japanese (10). Similarly, previous studies showed 
that the mutation c.500G>A (p.Arg167Gln) is associated 
with RCC and renal cysts in western populations, 
suggesting that this mutation causes VHL Type 1 (15, 16, 
27), while we found that this mutation in Families 3 and 
4 frequently caused Pheo, indicating that this mutation 
(c.500G>A; p.Arg167Gln) is likely linked to VHL Type 2 in 
the Chinese population.
Different family members bearing the same mutation 
could also show distinct phenotypes. It has been reported 
that members in the same family with a c.203C>G 
(Ser68Trp) mutation demonstrated variable penetrance 
of isolated Pheos (28). The proband did not manifest 
Pheo until he was age 63 years. By contrast, one of the 
proband’s six children presented with an isolated Pheo at 
age 23 years, and the proband’s sister developed a Pheo at 
the age of 24 years. In addition, two of her three children 
are carriers of the mutation and one of them was still 
asymptomatic at the age of 35, whilst the other had a Pheo 
when she was 12  years old. Taken together, these data 
indicate that many other factors, possibly environment, 
may affect the phenotypes induced by specific mutations. 
Therefore, it is necessary to characterize genotype-
phenotype correlation between different populations. In 
conclusion, better understanding genotype–phenotype 
correlation can not only advance our prediction of VHL 
disease-associated risks but also improve the diagnosis, 
surveillance and treatment of VHL.
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